Eupraxia Reports 90% and 88% Histologic Reductions and 66% Remission at Week 36
At 36 weeks, Cohort 9 (n=3) of Eupraxia’s Phase 1b/2a RESOLVE trial showed 90% and 88% EoEHSS reductions and a 72% drop in peak eosinophil count. Clinical remission persisted in 66% of patients and no drug-related serious adverse events were reported across 31 patients.
1. Cohort 9 Efficacy Outcomes
Patients in Cohort 9 (20×8 mg dose) exhibited a 90% reduction in EoE Histology Scoring System (EoEHSS) stage and an 88% grade reduction alongside a 72% drop in peak eosinophil count at week 36. Two out of three patients maintained a three-point reduction in the Straumann Dysphagia Index from weeks 8 through 36, meeting criteria for clinical remission.
2. Safety and Tolerability
EP-104GI was well tolerated across all dose cohorts, with 31 patients contributing over 230 patient-months of follow-up and zero drug-related serious adverse events. No cases of oropharyngeal candidiasis, adrenal insufficiency or glucose derangement were observed, including in a patient with type II diabetes.
3. Upcoming Phase 2b Trial
The randomized, placebo-controlled Phase 2b portion is recruiting adults for 120 mg (20×6 mg) and 160 mg (20×8 mg) doses of EP-104GI, with top-line data expected in Q4 2026. Additional open-label Phase 1b/2a data disclosures are planned in the coming months.